Chemed Corporation (BMV:CHE)
| Market Cap | 135.48B +21.8% |
| Revenue (ttm) | 47.96B +5.2% |
| Net Income | 5.09B +1.3% |
| EPS | 401.02 +10.5% |
| Shares Out | n/a |
| PE Ratio | 22.65 |
| Forward PE | 20.01 |
| Dividend | 45.61 (0.50%) |
| Ex-Dividend Date | Nov 16, 2026 |
| Volume | n/a |
| Open | 9,083.00 |
| Previous Close | 9,083.00 |
| Day's Range | 9,083.00 - 9,083.00 |
| 52-Week Range | 9,083.00 - 9,083.00 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Oct 27, 2026 |
About Chemed
Chemed Corporation provides hospice and palliative care services to patients through a network of physicians, doctors, registered nurses, home health aides, social workers, clergy, and volunteers primarily in the United States. The company operates through two segments: VITAS and Roto-Rooter segments. The company offers plumbing, drain cleaning, excavation, water restoration, and other related services to residential and commercial customers through company-owned branches, independent contractors, and franchisees. The company also provides dire... [Read more]
Financial Performance
In 2025, Chemed's revenue was $2.53 billion, an increase of 4.06% compared to the previous year's $2.43 billion. Earnings were $265.24 million, a decrease of -12.17%.
Financial numbers in USD Financial StatementsNews
Chemed Transcript: UBS Global Healthcare Conference
VITAS delivered strong 2026 growth through referral rebalancing, with a $32 million Florida cap cushion and continued demographic opportunity. Roto-Rooter sales grew 7.5%, but rising Google marketing costs pressure margins into 2027.
Chemed Corporation Declares Quarterly Dividend of 70 Cents
CINCINNATI, Nov. 06, 2026 (GLOBE NEWSWIRE) -- Chemed Corporation (NYSE:CHE) announced today that the Board of Directors has declared a quarterly cash dividend of 70-cents per share on the Company's ca...
Chemed management to meet with Oppenheimer
Meetings to be held in Boston on November 3-4 hosted by Oppenheimer.
Chemed Corporation to Present at the UBS 2026 Global Healthcare Conference
CINCINNATI, Nov. 02, 2026 (GLOBE NEWSWIRE) -- Chemed Corporation (NYSE: CHE) today announced that it will deliver a presentation at the UBS 2026 Global Healthcare Conference on Monday, November 9, 202...
Chemed price target raised to $585 from $548 at RBC Capital
RBC Capital raised the firm’s price target on Chemed (CHE) to $585 from $548 and keeps a Sector Perform rating on the shares. The company posted another strong result in…
Chemed price target raised to $675 from $650 at UBS
UBS raised the firm’s price target on Chemed (CHE) to $675 from $650 and keeps a Buy rating on the shares.
Chemed price target raised to $625 from $590 at Oppenheimer
Oppenheimer raised the firm’s price target on Chemed (CHE) to $625 from $590 and keeps an Outperform rating on the shares following quarterly results, with Vitas strength outweighing Roto-Rooter margi...
Chemed Earnings Call Transcript: Q3 2026
Q3 revenue rose 10.6% and adjusted diluted EPS increased 28.1%, led by VITAS growth. Roto-Rooter revenue advanced, but marketing and fuel costs pressured margins; FY2026 adjusted EPS is expected at or above the high end of guidance.
Chemed Earnings release: Q3 2026
Chemed released its Q3 2026 earnings on October 28, 2026, summarizing the period's financial results.
Chemed Quarterly report: Q3 2026
Chemed has published its Q3 2026 quarterly earnings report on October 28, 2026.
Chemed price target raised to $555 from $550 at BofA
BofA raised the firm’s price target on Chemed (CHE) to $555 from $550 and keeps a Neutral rating on the shares. Q3 EBITDA beat by 2% and EPS beat by…
Chemed upgraded to Buy from Hold at Jefferies
Jefferies upgraded Chemed (CHE) to Buy from Hold with a price target of $620, up from $520. The firm expects the shares to “gradually re-rate” toward 15-times EBITDA as the…
Chemed reports Q3 adjusted EPS $6.75, consensus $6.44
Reports Q3 revenue $690.94M, consensus $685.04M. The company said, “As of September 30, 2026, Chemed (CHE) had total cash and cash equivalents of $48.4 million and $236.0 million in long-term…
Chemed backs FY26 adjusted EPS view $25.00-$25.75, consensus $25.49
The company said, “Based on the Company’s financial results through September 30, 2026, we estimate that we will be at or slightly above the high-end of our full-year 2026 adjusted…
Chemed Reports Third-Quarter 2026 Results
CINCINNATI, Oct. 27, 2026 (GLOBE NEWSWIRE) -- Chemed Corporation (Chemed) (NYSE: CHE), which operates VITAS Healthcare Corporation (VITAS), the nation's largest providers of end-of-life care, and Roto...
Chemed To Report Third Quarter 2026 Earnings October 27, Related Conference Call To Be Held On October 28
CINCINNATI, Oct. 01, 2026 (GLOBE NEWSWIRE) -- Chemed Corporation (NYSE: CHE) today announced that it will release financial results for the third quarter ended September 30, 2026, on Tuesday, October ...
Chemed initiated with a Buy at UBS
UBS initiated coverage of Chemed (CHE) with a Buy rating and $650 price target The firm believes the company can achieve low-double-digit adjusted earnings growth going forward. Based on the…
Roto-Rooter Buys Largest Franchisee Territory
CINCINNATI, Sept. 16, 2026 (GLOBE NEWSWIRE) -- Roto-Rooter Services Company, a wholly owned subsidiary of Chemed Corporation ("Chemed") (NYSE: CHE) announced it has acquired the largest independent Ro...
Chemed Transcript: 2026 Jefferies Healthcare Services and Technology Conference
Second quarter results exceeded expectations, prompting raised guidance. VITAS continues to outperform, driven by operational improvements and Florida expansion, while Roto-Rooter has stabilized despite higher marketing costs. Demographic trends support strong hospice demand and workforce investments remain a priority.
Chemed Corporation to Present at the Jefferies 2026 Healthcare Services Conference
CINCINNATI, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Chemed Corporation (NYSE: CHE) today announced that it will deliver a presentation at the Jefferies 2026 Healthcare Services and Technology Conference on...
Chemed unit claimed to misdiagnose dementia patients, Capitol Forum says
The Capitol Forum stated in a post to X: “Chemed (CHE): Vitas Healthcare Misdiagnosed Dementia Patients and ‘Fudged’ Evaluation Scores in Order to Admit Them into Hospice; Expert Who Reviewed…
Chemed boosts quarterly dividend to 70c from 60c per share
Chemed (CHE) Corporation announced that the board of directors has declared a quarterly cash dividend of 70c per share on the company’s capital stock, payable on September 3 to shareholders…
Chemed price target raised to $590 from $500 at Oppenheimer
Oppenheimer raised the firm’s price target on Chemed (CHE) to $590 from $500 and keeps an Outperform rating on the shares following quarterly results. Overall, Vitas continues to shoulder the…
Chemed price target raised to $548 from $436 at RBC Capital
RBC Capital analyst Ben Hendrix raised the firm’s price target on Chemed (CHE) to $548 from $436 and keeps a Sector Perform rating on the shares. The company delivered another…
